Lansoprazole Capsules
ID: SPE2D2-25-R-0005Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/a6b786bc53914095ae13270395d8ab4f/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Lansoprazole capsules, specifically 30MG in 100 count bottles. This procurement aims to establish a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable supply of this essential pharmaceutical item. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or 215-737-6031, and are encouraged to set up automated notifications for updates on the solicitation through the DLA Bid Board System and Sam.Gov.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Lansoprazole Capsules
    Currently viewing
    Presolicitation
    Similar Opportunities
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Bicalutamide 50MG tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    LANSOPRAZOLE NATIONAL CONTRACT MODIFICATION
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is issuing a modification to the LANSOPRAZOLE NATIONAL CONTRACT. This modification aims to incorporate additional clauses to the existing contract. Lansoprazole is a medication used to treat stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). It belongs to a class of drugs known as proton pump inhibitors and helps reduce the amount of acid produced in the stomach. The modification to the contract will include the addition of specific clauses that may address various aspects such as pricing, delivery schedules, quality control, or any other relevant terms and conditions. For more information or inquiries, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 2157378677.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    PRAVASTATIN SODIUM TABLETS
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Pravastatin Sodium tablets. The tablets are available in 10MG, 20MG, and 80MG strengths, and will be packaged in bottle counts of 90 and 1000. This contract will establish a national supply source to provide the tablets for purchase by Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The solicitation is expected to be posted in January 2019.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.